azacitidine,decitabine,gilteritinib,venetoclax
mgi pharma,astellas,supergen,roche,Abbvie
['leukemia', 'gilteritinib', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders),(-dreamlike)', 'azacitidine,(-oral azaci),(-azacitidine oral)', 'leusm', 'decitabine', 'mds']
#ash22 #leusm ionescu: outcomes of post-allohct relapsed aml treated w hma/ven at single center (moffitt), n=58 (about 50:50 aza:dac), 7% also got gilteritinib. 42% cr/cri after median 1 but up to 5 cycles). odds of resp assoc w time to relapse (short worse) &amp; npm1/idhm (better). 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)